Pegfilgrastim
It is a pegylated form of the recombinant human granulocyte colonystimulating factor (GCSF) analog filgrastim. It serves to stimulate the level of white blood cells (neutrophils). The drug is prepared by coupling a 20 kDa polyethylene glycol (PEG) molecule to the N-terminus of the filgrastim protein. Pegfilgrastim has a human half-life of 15 to 80 hours, much longer than parent filgrastim (3-4 hours).Neutropenia during chemotherapy.
SC; 6mg once per chemotherapy cycle.
Hypersensitivity to filgrastim.
Spleen rupture, ARDS, Category C in pregnancy, sickle cell crisis.
Splenomegaly, splenic rupture, sickle cell crises, ARDS, bone pain, pain in extremity, myalgia, arthralgia, headache, nausea, vomiting, constipation, peripheral oedema, inj site reactions, skin rash, urticaria, erythema, flushing, thrombocytopenia, leukocytosis, antibody formation, sweet's syndrome; elevations in uric acid, alkaline phosphatase, lactate dehydrogenase, ALT and AST, Anaphylaxis.
Cytotoxic chemotherapy.
